Laney, Anthony Scott
(2006)
OPTIMIZATION OF A SEROLOGICAL ASSAY SYSTEM FOR ESTABLISHING INFECTION OF KAPOSI'S SARCOMA ASSOCIATED HERPESVIRUS (KSHV) IN MULTIPLE POPULATIONS AT VARYING LEVELS OF RISK.
Doctoral Dissertation, University of Pittsburgh.
(Unpublished)
Abstract
Background: Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8) is the etiologic agent of Kaposi's sarcoma (KS), multicentric Castleman's disease (MCD), and primary effusion lymphoma (PEL). KSHV is a nonubiquitous herpesvirus (~3% in the general US population) that can cause significant morbidity and mortality among immunocompromised hosts. However, routine surveillance of KSHV is lacking because diagnostic systems for viral identification are not of high enough sensitivity and specificity. This research describes a novel KSHV serological algorithm which increases sensitivity and specificity of KSHV detection beyond what has been previously reported.Methods: A novel KSHV assay algorithm based on a baculovirus-expressed LANA1-GST fusion protein was used with previously described KSHV lytic antigen ELISAs. Initial assay evaluation was performed using 90 case sera from persons with AIDS- KS and 100 blood donor controls. We identified two multi-antigen algorithms: one that maximized sensitivity and one that maximized specificity. Sera from patients requiring bone-marrow transplantation, cadaveric renal transplant donors (CRTD), patients with systemic lupus erythematosus (SLE) and subjects with primary (PPH) and secondary pulmonary hypertension were obtained for KSHV testing. Results: The highly sensitive algorithm yielded a sensitivity of 96% and a specificity of 94% and the highly specific algorithm a sensitivity of 93% and a specificity of 98%. Among CRTD, using the highly specific algorithm, overall seroprevalence was low at 4.0% (2/50) and similar to blood donors (P=0.46; OR=1.4; CI=0.14, 7.9). With the more specific algorithm, 8.0% (4/50) were infected compared to 6.4% (16/250) among blood donors (OR=1.3; CI=0.41,4.0; P=0.43). Among subjects requiring bone marrow transplantation seroprevalence was 3.0% and 10.0% and did not differ from blood donors (OR=2.0; 95% CI=0.10,122.9; P=0.50). Higher KSHV seroprevalence was observed among SLE patients using the specific algorithm (OR=6.0; 95% CI, 1.2-29.0) and the sensitive algorithm (OR=3.6; 95% CI, 1.1-12.2) though this is likely due to antigenic cross-reactivity as opposed to actual infection. Among patients with PPH we found no evidence of KSHV infection (0/19).Conclusions: We used a systematic approach to standardize the assessment of KSHV infection rates and examined seroprevalence rates among high-risk populations of clinical interest. KSHV is of public health importance because it leads to cancer in immunocompromised hosts. Future studies of KSHV should focus on the cost-effectiveness of implementing surveillance systems such as the one described here, which could potentially lead to a marked reduction in KSHV-associated morbidity and mortality.
Share
Citation/Export: |
|
Social Networking: |
|
Details
Item Type: |
University of Pittsburgh ETD
|
Status: |
Unpublished |
Creators/Authors: |
Creators | Email | Pitt Username | ORCID |
---|
Laney, Anthony Scott | asl7@pitt.edu | ASL7 | |
|
ETD Committee: |
|
Date: |
3 February 2006 |
Date Type: |
Completion |
Defense Date: |
2 December 2005 |
Approval Date: |
3 February 2006 |
Submission Date: |
6 December 2005 |
Access Restriction: |
No restriction; Release the ETD for access worldwide immediately. |
Institution: |
University of Pittsburgh |
Schools and Programs: |
School of Public Health > Epidemiology |
Degree: |
PhD - Doctor of Philosophy |
Thesis Type: |
Doctoral Dissertation |
Refereed: |
Yes |
Uncontrolled Keywords: |
Epidemiology; HHV-8; KSHV |
Other ID: |
http://etd.library.pitt.edu/ETD/available/etd-12062005-084847/, etd-12062005-084847 |
Date Deposited: |
10 Nov 2011 20:08 |
Last Modified: |
15 Nov 2016 13:53 |
URI: |
http://d-scholarship.pitt.edu/id/eprint/10089 |
Metrics
Monthly Views for the past 3 years
Plum Analytics
Actions (login required)
|
View Item |